Background: Pemphigus is a severe blistering disorder caused by autoantibodies to desmogleins 1 and 3. Because some patients with pemphigus never enter into remission, new immunosuppressants are warranted. Rituximab is a chimeric monoclonal antibody binding to the CD20 antigen on B cells, which proved to be effective in recalcitrant pemphigus. Objectives: To evaluate the efficacy and safety of rituximab in refractory pemphigus and to investigate its effects on the autoantibody profile. Patients and Methods: Six patients with recalcitrant pemphigus were treated. Rituximab was administered intravenously at a dosage of 375 mg/m2 body surface once weekly for 4 weeks. Results: Three pemphigus foliaceus patients and 1 with mucocutaneous pemphigus vulgaris (PV) showed complete response over a follow-up period of up to 18 months. In one oral PV, control of the disease was achieved using pulse therapy with cyclophosphamide following rituximab withdrawal. In one PV with vegetating features, good improvement was obtained after 6 rituximab infusions. All patients tolerated the treatment well. Anti-desmoglein autoantibodies significantly decreased only in pemphigus foliaceus. Conclusions: This study highlights that rituximab is a valuable drug for refractory pemphigus, although the response of mucous membranes and cutaneous folds may be delayed.

Keywords:
Anti-CD20 monoclonal antibody, Rituximab, Pemphigus vulgaris, Pemphigus foliaceus, Pemphigus vegetans
1.
Hertl M, Veldman C: Pemphigus-paradigm of autoantibody-mediated autoimmunity. Skin Pharmacol Appl Skin Physiol 2001;14:408–418.
2.
Ng PP, Thng ST: Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA. Dermatology 2005;210:319–321.
3.
Nishifuji K, Amagai M, Kuwana M, et al: Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 2000;114:88–94.
4.
Herbst A, Bystryn JC: Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42:422–427.
5.
Toth GG, Jonkman MF: Therapy of pemphigus. Clin Dermatol 2001;19:761–767.
6.
Borradori L, Lombardi T, Samson J, et al: Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol 2001;137:269–272.
7.
Heizmann M, Itin P, Wernli M, et al: Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment of paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001;66:142–144.
8.
Salopek TG, Logsetty S, Tredget EE: Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002;47:785–788.
9.
Hermann G, Hunzelmann N, Engert A: Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003;148:602–603.
10.
Cooper HL, Healy E, Theaker JM, et al: Treatment of resistant pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003;28:366–368.
11.
Virgolini L, Marzocchi V: Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003;88:ELT24.
12.
Goebeler M, Herzog S, Brocker EB, et al: Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003;149:899–901.
13.
Dupuy A, Viguier M, Bedane C, et al: Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91–96.
14.
Espana A, Fernandez-Galar M, Lloret P, et al: Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004;50:974–976.
15.
Morrison LH: Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004;51:817–819.
16.
Wenzel J, Bauer R, Bieber T, et al: Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005;85:185–186.
17.
Arin MJ, Engert A, Krieg T, et al: Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620–625.
18.
Belgi AS, Azeez M, Hoyle C, et al: Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006;31:143.
19.
Reff M, Carner K, Chambers K, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435–445.
20.
Tedder T, Engel P: CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450–454.
21.
Smith MR: Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359–7368.
22.
Grillo-Lopez AJ, White CA, Dallaire BK, et al: Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000;1:1–9.
23.
Quartier P, Brethon B, Philippet P, et al: Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511–1513.
24.
Specks U, Fervenza FC, McDonald TJ, et al: Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836–2840.
25.
Stasi R, Pagano A, Stipa E, et al: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98:952–957.
26.
Niedermeier A, Worl P, Barth S, et al: Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006;16:266–270.
27.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772–1779.
28.
Bhol K, Natarajan N, Mohimen, et al: Correlation of peptide specificity and IgG subclass with pathogenic and non-pathogenic autoantibodies in pemphigus vulgaris. Proc Natl Acad Sci USA 1995;92:5239–5243.
29.
Harris DP, Haynes L, Sayles PC, et al: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;6:475–482.
30.
Hertl M, Veldman C: T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003;2:278–283.
31.
Schmidt E, Hunzelmann N, Zillikens D, et al: Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006;31:503–508.
32.
Skok J, Poudrier J, Gray D: Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th 1 development. J Immunol 1999;163:4284–4291.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.